Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India

Himanshu Yadav, Snigdha Sen, Tirupati Nath, Shefali Mazumdar, Anu Jain, Pinky Verma, Preeti Gupta

Purpose: An unprecedented surge has been noted in rhino-orbital-Cerebral mucormycosis (ROCM) in times of current COVID-19 pandemic. The present prospective study aims to evaluate clinico-epidemiological profile, risk factors, management, and outcome of the cases of ROCM that presented to our tertiary care center during the study period from April to June 2021. Methods: All patients were subjected to complete history taking, ophthalmological examination, and imaging studies. The patients were staged and were treated with intravenous liposomal amphotericin B (AMB) and sino-nasal debridement of local necrotic tissue. Transcutaneous retrobulbar AMB (TRAMB), orbital decompression, and exenteration were instituted as indicated. All patients were followed up for a minimum of 6 months before arriving at the final outcome. Statistical analysis was performed. Results: A total of 49 patients presented during the study period, with a mean age of 42.2 years. The major risk factors included uncontrolled diabetes (89.8%), COVID-19 positivity (51.02%), and concurrent steroid use (38.77%). The most common presenting symptom was facial pain/swelling (43.65%), while the most common presenting sign was deterioration in vision (75.51%). Intravenous liposomal AMB was given to all patients along with sino-nasal debridement (85.71%), TRAMB (57.14%), orbital decompression (14.28%), and exenteration (12.24%). Overall, mortality at 6 months was 22.45% (11 patients). Age more than 60 years, intracranial extension, and HbA1c of more than 8.0% were observed to be statistically significant indicators of mortality. Conclusion: Early suspicion and timely diagnosis of mucormycosis at rhino-orbital stage is warranted in order to salvage life as well as visual function. TRAMB may prove as potentially favorable treatment modality in cases with limited orbital involvement.

Key words: COVID-associated mucormycosis (CAM), rhino-orbital-cerebral mucormycosis (ROCM), transcutaneous retrobulbar amphotericin B (TRAMB)

The ongoing pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to health implications of unprecedented degree. We are still unravelling the far-fetched health implications and long-term complications associated with the coronavirus disease 2019 (COVID-19). Initial reports on ocular manifestations in patients with COVID-19 describe mainly self-limiting conjunctivitis and rare manifestations that include optic neuritis, vascular occlusions, ocular motor cranial neuropathies, and rhino-orbital-cerebral mucormycosis (ROCM).[1]

ROCM is a rare but life-threatening, invasive fungal infection that often occurs in immuno-compromised persons. Diabetic ketoacidosis remains the most common predisposing event, associated with around two-thirds of the cases of ROCM.[2] The condition originates in the nose and paranasal sinuses but is often undiagnosed until orbital spread, indicating its grave prognosis. The fungal hyphae invade the surrounding bone and soft tissue through vascular thrombosis causing subsequent tissue infarction and may eventually infiltrate the brain leading to fatal complications.[3,4]

During pre COVID-19 times, India had highest global burden of mucormycosis with about 140 cases per million populations.[5] The figures have increased exponentially with resurgence of COVID-19 cases in the country. COVID-19 produces a hypoxic milieu with high glucose levels, high ferritin levels, and impaired phagocytic activity of leukocytes due to immunosuppression by the virus as well as the rampant steroid use for the management. Also, hydroxychloroquin (HCQS) has been shown to impair autophagy and phagocytosis, further weakening host immune response.[6] COVID-19 in diabetics provided the most facilitatory condition for proliferation of fungal hyphae. Use of industrial grade oxygen to fill for shortage of medical oxygen, extended hospital stay with risk of nosocomial infection, use of targeted immunosuppressants like tocilizumab, and associated comorbidities contribute as other risk factors for rise in incidence of COVID-19-associated ROCM.[7,8]

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Cite this article as: Yadav H, Sen S, Nath T, Mazumdar S, Jain A, Verma P, et al. Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India. Indian J Ophthalmol 2022:70:2163-8.
This study intends to report the clinic-epidemiological profile and treatment outcome of COVID-19-associated ROCM cases that presented at our center during April–June 2021.

**Methods**

We conducted a prospective observational study on cases presenting with ROCM to our tertiary care from April to June 2021. Ethical approval for the study was sought from the institutional Ethics Committee. Evaluation at presentation included a detailed history, complete ophthalmic, oto-rhino-laryngeal and neurological examination, nasal endoscopy with biopsy, and haematological tests, to assess the extent of disease. History of COVID-19 vaccination was elicited and patients were categorized as unvaccinated (no dose received or less than 2 weeks of the first dose), partially vaccinated (more than 2 weeks of the first dose and/or less than two weeks of second dose), or fully vaccinated (more than two weeks of the second dose). History of COVID-19, past or concurrent, including diagnostic test for COVID-19 was recorded. The diagnosis of definite COVID-19 was based on either of the following: reverse transcription polymerase chain reaction (RT-PCR) test on nasopharyngeal or oropharyngeal swabs, rapid antigen test, or computed tomography (CT) chest scores in the absence of a positive RT-PCR test in a clinically symptomatic case. Suspected COVID-19 cases were the ones who were either kins of definite COVID-19 patients or had a recent history of fever and cough/cold in self or family members but had not undergone diagnostic tests for COVID-19. Medical records of hospitalization for COVID-19 treatment were reviewed, elucidating severity of disease, duration of hospital stay, use of steroids and other immune-suppressants, and requirement of supplemental oxygen or mechanical ventilation. History of any comorbid ailment and its treatment was also elicited. Imaging studies included magnetic resonance imaging (MRI) or CT scan of orbits, brain, and paranasal sinuses with or without contrast. Hematology included complete hemogram, blood sugar, glycosylated hemoglobin, and renal function tests. The patients were classified into Proven, Probable, or Possible Mucormycosis as per the case definition suggested by the European Organization for Research and Treatment of Cancer and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) and modified by Honavar et al.\[10,11\]. A patient with symptoms and signs of ROCM, in the clinical setting of concurrent or recently treated COVID-19, was labeled as possible ROCM. If clinical features were supported by diagnostic nasal endoscopy findings, contrast-enhanced MRI, or CT scan, patient was categorized as probable ROCM. Proven ROCM was defined as clinic-radiological features along with microbiological confirmation on direct microscopy and/or culture or histopathology.

All the patients were staged at admission, according to the staging system proposed by Honavar,\[11\] and were managed in accordance with the modified EORTC/MSG guidelines.\[11\] Intravenous liposomal amphotericin B (AMB) in recommended doses was the mainstay of treatment in all the patients. Therapeutic measures also included control of the general condition, underlying risk factors, and complications, together with antibiotics to prevent secondary bacterial infection. Functional endoscopic sinus surgery (FESS) was performed to debride sino-nasal necrotic tissue. Orbital intervention included transcutaneous retrobulbar AMB (TRAMB), orbital decompression, and orbital exenteration. Exenteration was undertaken in patients with severe orbital disease (stages 3 and 4) after medicine and anesthesia clearance. TRAMB was employed as adjunctive treatment modality in patients who had limited orbital involvement or those who had extensive orbital involvement but were unfit or nonconsenting for exenteration. One millimeter liposomal AMB in a concentration of 3.5 mg/mL was used as one dose of TRAMB. A minimum of three and a maximum of nine alternate day injections were given. The patients were subsequently watched for possible side effects of retrobulbar injection such as neurotoxicity, compartment syndrome, and raised intraocular pressure. Orbital decompression and debridement instead of exenteration were performed in a few patients with severe orbital disease.

All the patients were followed up for a period of at least 6 months from presentation to record the final outcome.

The data was analyzed using SPSS (IBM SPSS Statistics 20, SPSS Inc., Chicago, IL, USA) and Microsoft Excel (Version 16.49).

**Table 1: Epidemiological profile of patients**

| Patient characteristics (n=49) | Number (%) |
|--------------------------------|------------|
| **Age, years**                  |            |
| ≤40                            | 13 (26.53) |
| 41-59                          | 20 (40.82) |
| ≥60                            | 16 (32.65) |
| **Gender**                      |            |
| Male                           | 32 (65.31) |
| Female                         | 17 (34.69) |
| **Association with COVID-19**   |            |
| No COVID-19                    | 24 (48.98) |
| Definite COVID-19              | 23 (46.94) |
| Suspected COVID-19             | 02 (4.08)  |
| **Vaccination status**         |            |
| Unvaccinated                   | 44 (89.79) |
| Partially vaccinated           | 05 (10.20) |
| Fully vaccinated               | 00         |
| **Comorbidities**              |            |
| Diabetes mellitus              | 33 (67.34) |
| Hypertension                   | 14 (28.57) |
| Coronary artery disease        | 01 (2.04)  |
| Others                         | 01 (2.04)  |
| **Glycosylated haemoglobin level at presentation** |          |
| <5.6 (Normal)                  | 03 (6.1)   |
| 5.7-6.4 (Prediabetic)          | 02 (4.1)   |
| ≥6.5 (Diabetic)                | 44 (89.8)  |
| **History of oxygen therapy**  |            |
| Yes                            | 14 (28.57) |
| No                             | 35 (71.43) |
| **History of steroid use**     |            |
| Yes                            | 19 (38.77) |
| No                             | 26 (53.06) |
| Unknown                        | 04 (8.16)  |
| **No. of days from COVID-19 diagnosis to presentation for ROCM (n=25)** |   |
| Concurrent                     | 04         |
| <1 month                       | 18         |
| >1 month                       | 03         |
Table 2: Clinical and radiological features (n=49)

| Feature                          | Number (%)       |
|----------------------------------|------------------|
| **Presenting symptoms**          |                  |
| Facial pain/swelling             | 21 (42.86%)      |
| Drooping of eyelid               | 18 (36.73%)      |
| Nasal discharge/bleeding         | 18 (36.73%)      |
| Decreased vision                 | 17 (34.69%)      |
| Double vision                    | 10 (20.41%)      |
| Protrusion of eye                | 09 (18.37%)      |
| Altered sensorium                | 05 (10.20%)      |
| **Presenting signs**             |                  |
| Ptosis                           | 21 (42.86%)      |
| Ophthalmoplegia                  | 21 (42.86%)      |
| Visual deterioration             |                  |
| No PL                            | 09 (18.37%)      |
| 6/60 to PL+                      | 15 (30.61%)      |
| 6/18 to 6/60                     | 13 (26.53%)      |
| Better than 6/18                 | 12 (24.49%)      |
| Proptosis                        | 13 (26.53%)      |
| Keratopathy                      | 12 (24.49%)      |
| Nasal/palatal eschar             | 02 (4.08%)       |
| Periocular/Facial hypoesthesia   | 03 (6.12%)       |
| Fundus changes                   |                  |
| CRAO*                            | 02 (4.08%)       |
| CRVO*                            | 01 (2.04%)       |
| Radiology                        |                  |
| Paranusal sinus                  |                  |
| Diffuse involvement             | 45 (22.4%)       |
| Bilateral involvement           | 22 (44.90%)      |
| Orbit                            |                  |
| Bilateral involvement           | 04 (8.16%)       |
| Brain                            |                  |
| Cavernous sinus thrombosis       | 09 (18.37%)      |
| ICA* Invasion                    | 03 (6.12%)       |
| Frontal lobe abscess            | 01 (2.04%)       |
| Others                           | 03 (6.12%)       |
| Stage of disease at presentation |                  |
| 1                                | 01 (2.04%)       |
| 2                                | 23 (46.94%)      |
| 3                                | 11 (22.45%)      |
| 4                                | 14 (28.57%)      |

* CRAO, Central retinal artery occlusion; CRVO, central retinal vein occlusion; ICA, internal carotid artery

The Fisher’s exact tests were used to compare outcomes. For all tests, \( P \) values \( \leq 0.05 \) were defined as statistically significant.

**Results**

A total of 49 cases of ROCM presented over a period of 3 months, 32 (65.31%) of which were male. The mean age of the cases was 42.2 (±12.7) years, with about two-thirds of the patients belonging to the productive age group of less than 60 years [Table 1]. A positive history of COVID-19 was elicited in only about half of the patients; with confirmed COVID-19 illness in only 23 patients. Three patients were concurrently positive for SARS-CoV-2, had moderate to severe disease, and were treated for COVID-19 in isolation wards in accordance with the national guidelines for COVID-19 issued by Ministry of Health and Family Welfare (MoHFW) that included systemic steroids, HCQ5, and oxygen supplementation.\[^{12}\] History of partial vaccination was elicited in 5 (10.2%) patients, and none of the patients had undergone complete COVID-19 vaccination. History of preexisting diabetes mellitus was recorded in 33 (67.33%) patients, although glycosylated hemoglobin (HbA1c) levels at presentation were found in diabetic range in most of the patients. Comorbidities other than diabetes were present in 16 patients and included mainly hypertension. Coronary artery disease and chronic kidney disease were present in one patient each. Table 1 depicts the epidemiological profile and distribution of various risk factors among all the study patients.

Table 2 elucidates the clinico-radiological features of all the patients. Most common presenting symptom was facial pain/swelling (42.86%), followed by drooping of eyelid and nasal discharge/bleeding (37.5%). Significant deterioration in vision was recorded as the most frequent presenting sign, followed by ophthalmoplegia and ptosis. Forty-seven (95.9%) patients were categorized as proven cases of ROCM, while the rest two were probable cases.

On radiological assessment, 32 (65.30%) cases demonstrated orbital infiltration with four cases (8.3%) having bilateral involvement. Of the 16 (33.3%) cases with central nervous system (CNS) involvement, 9 (18.4%) had developed cavernous sinus infiltration, three (6.1%) cases developed internal carotid artery involvement, and one (1.9%) developed frontal lobe abscess.

FESS was performed in 42 (85.71%) of the patients. Table 3 depicts the stage-wise frequency of various orbital interventions. TRAMB was the most commonly employed orbital intervention, undertaken in 28 patients (57.14%). Of the 28 patients, 13 were the ones that were stage 2 at initial presentation but progressed during the course of disease and showed clinical/radiological sign of orbital involvement. Rest of the patients receiving TRAMB were stage 3 and stage 4 patients with significant orbital involvement. Orbital decompression and orbital exenteration were performed in four (8.16%) and six (12.24%) patients, respectively [Figs. 1 and 2].

Forty-two (85.71%) patients were discharged with either stable or improved status. The mean period of hospitalization was 23 ± 11 days. Stepdown therapy with oral posaconazole could be instituted in 20 (40.81%) patients.

At 6 months follow-up, overall mortality was found to be 22.45% (11 patients), while complete loss of vision and ocular motility was noted in 11 and 16 surviving patients, respectively. Table 4 elucidates the final outcome in patients with severe orbital disease, but the numbers in each group are too less to arrive at any statistical relevance. Among the nonsurvivors, 81.82% had age more than 60 years \( (P < 0.05) \), 90.90% had intracranial involvement \( (P < 0.05) \), and all patients had HbA1c >8.0% \( (P < 0.05) \).

**Discussion**

Mucormycosis is an infrequent but fulminantly invasive, and potentially lethal infection caused by a group of aseptate filamentous fungi known as mucorales.\[^{10}\] The clinical hallmark of mucormycosis is vascular invasion resulting in thrombosis
Table 3: Stage-wise frequency of orbital intervention

| Stage of Disease | No. Of Patients | TRAMB* | Orbital Decompression | Exenteration |
|------------------|-----------------|--------|-----------------------|--------------|
| Stage 2 (Paranasal sinus involvement with no/minimal orbital involvement) | | | | |
| 2a               | 02              |        |                      |              |
| 2b               | 07              | 03     |                      |              |
| 2c               | 10              | 07     |                      |              |
| 2d               | 04              | 03     |                      |              |
| Stage 3 (Orbital involvement) | | | | |
| 3a               | 04              |        |                      |              |
| 3b               | 04              |        |                      |              |
| 3c               | 03              | --     | 02                    | 01           |
| Stage 4 (Intracranial involvement) | | | | |
| 4a               | 03              | 01     | 01                    | 01           |
| 4b               | 04              | 03     | 01                    | --           |
| 4c               | 07              | 03     | --                    | 04           |

*Transcutaneous Retro-bulbar Amphotericin B

Table 4: Outcome of various orbital treatment measures in patients with significant orbital involvement

| Orbital intervention (No. of patients) | Survivors at 6 months |
|----------------------------------------|-----------------------|
| Stage 3                                |                       |
| TRAMB (08)                             | 06                    |
| Orbital decompression (02)             | 02                    |
| Exenteration (01)                      | 00                    |
| Stage 4                                |                       |
| TRAMB (07)                             | 06                    |
| Orbital decompression (02)             | 01                    |
| Exenteration (05)                      | 01                    |

Table 5: Comparison of present study with that of other recent studies on ROCM

| Study (n) | Follow-up duration | Exenteration (%) | TRAMB (%) | Mortality (%) |
|-----------|--------------------|------------------|-----------|---------------|
| Current (49) | 6 months          | 12.24            | 57.14     | 22.4          |
| Sen[25] (2826) | 14.4±2.1 days    | 15.0             | 22.0      | 14.0          |
| Dave[26] (58)  | 5 months          | 38.0             | 1.72      | 34.0          |
| Ravani[27] (31) | 2.5 months       | 13.0             | --        | 10.0          |
| Walia[28] (540) | 3 months         | 5.0              | 51.85     | 9.25          |
| Moorthy[29] (18) | --               | 39.0             | --        | 33.0          |

and tissue infarction/necrosis. Apart from ROCM, there may be different clinical presentations depending upon the anatomic site involvement and associated defect in host defense. Diabetics in ketoacidosis typically develop the rhino-cerebral form of the disease and may rarely develop pulmonary or disseminated disease, while neutropenia and excessive steroid therapy predisposes a person to mainly pulmonary and disseminated mucormycosis.[14,15] Severe malnutrition is another risk factor that may predispose a person to gastrointestinal mucormycosis.[16] Cutaneous or subcutaneous mucormycosis may result from local trauma and skin maceration.[8] With unpredictable surge of COVID-19 cases in India and globally, a monumental rise in the cases of mucormycosis has been noted. A systematic review and meta-analysis by Masuza et al.[17] observed that COVID-associated mucormycosis (CAM) constitutes 0.3% of COVID-19 coinfections.

The average incidence of mucormycosis reported from different case series in India during the pre-COVID-19 era has ranged from 9.5 to 24.5 cases per year with a clear male preponderance.[18] We report a much higher rate of ROCM cases presenting to our hospital during the COVID-19 pandemic in comparison to the same period in the previous years. Male gender predominance, similar to that reported in previous studies, may be due to their greater involvement in outdoor chores. Two-thirds of our patients belonged to productive age group, indicating significant loss of man-days due to high mortality and morbidity associated with the disease.

Only about half of our cases had a positive association with SARS-CoV-2 infection, similar to that in a case series from Egypt by Fouad and co-workers.[19] Ravani et al.[20] also reported that a total of 38.70% patients in their series of 31 cases had no positive history of COVID-19 and steroid use. We cannot rule out a prior undocumented, untreated, or asymptomatic infection with SARS-CoV-2 in rest of our patients. Possible implication of COVID-19 in the development of ROCM may include impaired host defenses against the fungus by virus-induced lymphopenia or the therapeutic use of corticosteroids and/or HCQs, both likely to impair phagocytic immune-cell response, which is the major defense mechanism against mucormycosis.[10]

The national guidelines by MoHFW recommended prophylactic and therapeutic use of HCQS during both first and second wave of SARS-CoV-2, despite the United States Food and Drug Administration declaring its use unsafe outside of a hospital.[22,23] Self-medication with HCQS was fairly common practice as a preventive and treatment agent against SARS-CoV-2 without any strong evidence for its use.[23] It is worth noting that the widespread use of HCQS as measure against SARS-CoV-2 infection may be among the few factors responsible for surge in mucormycosis cases during the pandemic.

Deranged blood sugar was observed to be the most common risk factor, present in about 90% of our patients. Various other
Facial pain and puffiness was seen as the most common presenting symptom followed by drooping of eyelid and nasal discharge and/or bleeding. Early suspicion and timely diagnosis of mucormycosis is imperative to minimize morbidity and mortality associated with the disease. If subtle facial pain and nasal blockage is neglected by the patient and the primary healthcare provider, the diagnosis may be missed until the orbit is involved. Most common presenting signs in our study were those related to orbital involvement, that is, visual deterioration, ptosis, and ocular motility restriction. Nasal or palatal black eschar clinches the diagnosis but was seen in a few of our patients compared to one-third of the cases in multi-centric case series by Dave et al.[26] Further, intracranial involvement occurs from invasion of superior orbital fissure, ophthalmic vessels, cribriform plate, and not uncommonly, through carotid artery. One-third of the patients in our study showed intracranial extension, mainly in the form of cavernous sinus infiltration. One of the cases developed frontal lobe abscess. Hoenigl and co-workers have evaluated data from 18 countries and have reported intracranial involvement in 37% of the cases.[25]

From 2015 onwards, a therapeutic algorithm incorporating transcutaneous retrobulbar amphotericin B (TRAMB) for moderate orbital disease has been employed in the routine management of invasive fungal rhino-orbital sinusitis (IFROS) cases.[26] Ashraf et al.[27] have found that IFROS patients who were treated with a modified treatment protocol including TRAMB had a lower risk of disfiguring exenteration without a perceptible increase in the risk of mortality. Sen et al.[28] observed usage of intraorbital AMB in 22% cases for a median of two (range, 1–9) injections. Dave and co-workers have reported use of TRAMB in one of their 58 cases, which had localized orbital apex involvement and resulted in complete regain of ocular motility.[24] Safi reports resolution of ptosis and ophthalmoplegia in a case of ROCM with associated cerebritis with adjuvant TRAMB therapy.[29] Walia et al.[30] instituted TRAMB in 51.8% cases and reported an overall mortality of 9.25%. The current study observed favorable outcome in cases with mild orbital disease in terms of function recovery with TRAMB. In cases of severe orbital disease with or without cranial extension, the current study noted a better survival, with TRAMB therapy, although statistically unrelated. There is paucity of data on efficacy and safety profile of TRAMB, and well-designed prospective randomized studies are advocated to impart better clarity on the topic.

Mortality rates have varied considerably in recent Indian studies on CAM. Table 5 depicts the comparison of orbital intervention, follow-up, and mortality in the current study with that reported in other recent literature. With TRAMB having better survival benefits and being globe-salvaging option, the call for orbital exenteration needs to be reviewed especially in patients with compromised lung function due to COVID-19 and resultant anesthesia risks. In our experience, orbital decompression and debridement appear to be a better alternative to exenteration in cases of extensive orbital involvement.

**Conclusion**

CAM has emerged as an enormous threat to life and vision of patients. Uncontrolled diabetes mellitus and multifactorial immune suppression associated with COVID-19 plays
the pivotal role. Further research should aim to explicate whether a causal link exists between COVID-19 and ROCM. Early suspicion and timely diagnosis of mucormycosis at rhino-orbital stage is warranted in order to salvage life as well as visual function. TRAMB may serve as a favorable treatment modality in cases with limited orbital involvement.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**References**

1. Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and eye: A review of ophthalmic manifestations of COVID-19. Indian J Ophthalmol 2021;69:488-509.

2. McNulty JS. Rhinocerebral mucormycosis: Predisposing factors. Laryngoscope 1982;92:1140-3.

3. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Otolaryngol 1977;103:600-4.

4. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: A clinicopathologic study of 33 cases. Medicine 1986;65:113-23.

5. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi 2019;5:26. doi: 10.3390/jf5010026.

6. Devarajan A, Vaseghi M. Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights. Redox Biol 2021;38:101810. doi: 10.1016/j.redox.2020.101810.

7. Subauste CS. Autophagy as an antimicrobial strategy. Expert Rev Antifungal Ther 2009;7:743-52.

8. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis Pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556LP-69.

9. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146. doi: 10.1016/j.dsx.2021.05.019.

10. Pauw BD, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus Group. Clin Infect Dis 2008;46:1813-21.

11. Honavar SG. Code mucor: Guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021;69:1361-5.

12. Clinical Management Protocol: COVID-19. Ministry of health & family Welfare, government of India directorate general of health services (EMR division). Available from: https://www.mohfw.gov.in/pdf/ClinicalManagementProtocolforCOVID19dated27062020.pdf.

13. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012;54(Suppl 1):S16-22.

14. Verma GR, Lobo DR, Walker R, Bose S M, Gupta KL. Disseminated mucormycosis in healthy adults. J Postgrad Med 1995;41:40-2.

15. Sarrami AH, Setareh M, Izadinejad M, AfrsharMoghaddam N, Baradaran-Mahdavi MM, Meidani M. Fatal disseminated mucormycosis in an immunocompetent patient: A case report and literature review. Int J Prev Med 2013;4:1468-71.

16. Kaur H, Ghosh A, Rudramurthy SM, Chakrabarti A. Gastrointestinal mucormycosis in apparently immunocompetent hosts-A review.

17. Musuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Saifdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis. PLoS One 2021;16:e0251170.

18. Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms 2021;9:523. doi: 10.3390/microorganisms9030523.

19. Fouda YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour DM, Ashour MM. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. Front Med (Lausanne) 2021;8:645270. doi: 10.3389/fmed.2021.645270.

20. Ravanis SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol 2021;69:1563-8.

21. US Food and Drug Administration. FDA Cautions Against use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems. 2020. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against -use-hydroxychloroquine-or-chloroquine -covid-19-outside-hospital-setting-or.

22. Chauhan V, Thakur S. State of the globe: The frenzy of self-medication, cocktail regimens and everchanging guidelines on SARS-CoV-2. J Global Infect Dis 2021;13:65-6.

23. Aranjani JM, Manuel A, Abdul Razack HI, Mathew ST. COVID-19–associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLoS Negl Trop Dis 2021;15:e0009921.

24. Dave TV, Gopinathan Nair A, Hegde R, Vithalani N, Desai S, Adulkar N, et al. Clinical presentations, management and outcomes of rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19: A multi-centric study. Ophthalmic Plast Reconstr Surg 2021;37:488-95.

25. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Hoenigl M, Fehrenbacher L, et al. The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries. Lancet Microbe 2022 Jan 25. doi: 10.1016/S2666-5247(21)00237-8.

26. Karin-Hajdu E, Hirabayashi KE, Vagefi MR, Kersten RC. Invasive fungal sinusitis: Treatment of the orbit. Curr Opin Ophthalmol 2017;28:322-33.

27. Ashraf DC, Idowu OO, Hirabayashi KE, Karin-Hajdu E, Grob SR, Winn BJ, et al. Outcomes of a modified treatment ladder algorithm using retrobulbar amphotericin B for invasive fungal rhino-orbital sinusitis. Am J Ophthalmol 2021. doi: 10.1016/j.ajo.2021.05.025.

28. Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol 2021;69:1670-92.

29. Safi M, Ang MJ, Patel P, Silkiss RZ. Rhino-orbital-cerebral mucormycosis (ROCM) and associated cerebritis treated with adjuvant retrobulbar amphotericin B. Am J Ophthalmol Case Rep 2020;19:100771. doi: 10.1016/j.ajoc.2020.100771.

30. Walia S, Bhaïsare V, Rawat P, Kori N, Sharma M, Gupta N, et al. COVID-19-associated mucormycosis: Preliminary report from a tertiary eye care centre. Indian J Ophthalmol 2021;69:3685-9.

31. Mookthry A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multicentric analysis. J Maxillofac Oral Surg 2021;20:418-25.